Abstracts tagged "clinical trial"

Abstract Number: 1330 • ACR Convergence 2021
Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Philip Mease¹, Philip S Helliwell², Dafna Gladman³, Denis Poddubnyy⁴, Xenofon Baraliakos⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Xie Xu⁸, Shihong Sheng⁸, Stephen Xu⁸, May Shawi⁹, Désirée van der Heijde¹⁰ and Atul Deodhar¹¹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Oregon Health & Science University, Portland, OR
Background/Purpose: Guselkumab (GUS), a selective IL-23p19 inhibitor, resulted in greater mean improvements in BASDAI scores vs placebo (PBO) at W24 among patients (pts) with active…
Abstract Number: 1585 • ACR Convergence 2021
Suprascapular Nerve Block for the Treatment of Adhesive Capsulitis
Ernst Shanahan¹, Elizabeth Briggs¹, Tiffany Gill², Catherine Hill³ and Tim Morris⁴, ¹SA Health, Adelaide, Australia, ²University of Adelaide, Adelaide, Australia, ³Queen Elizabeth Hospital, Woodville, Australia, ⁴Flinders University, Adelaide, Australia
Background/Purpose: To investigate the value of suprascapular nerve block (SSNB) as a treatment option for adhesive capsulitis.Methods: Patients with adhesive capsulitis confirmed by a rheumatologist…
Abstract Number: 1739 • ACR Convergence 2021
SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials
Susan Manzi¹, Richard Furie², Eric Morand³, Yoshiya Tanaka⁴, Gabriel Abreu⁵, Catharina Lindholm⁵ and Raj Tummala⁶, ¹Allegheny Health Network, Pittsurgh, PA, ²Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ³Monash University, Melbourne, Australia, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity versus placebo in patients with moderate…
Abstract Number: 1801 • ACR Convergence 2021
The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis
Elaine Husni¹, Sona Kamat², Keri Stenger³, Rebecca Bolce³, Thorsten Holzkaemper⁴, Cameron Helt³, So Young Park³, Jeffrey Lisse⁵ and Luca Idolazzi⁶, ¹Cleveland Clinic, Cleveland, OH, ²St Louis University, Saint Louis, MO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Bad Homburg, Germany, ⁵Eli Lilly and Company, Tucson, AZ, ⁶University of Verona, Verona, Italy
Background/Purpose: It is important to understand how to select among the multiple treatment options for active psoriatic arthritis (PsA). Since individual patient domains may influence…
Abstract Number: 0411 • ACR Convergence 2021
Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata² and Shinichi Sato², ¹Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: The exact role of interleukin-17 in systemic sclerosis (SSc) has not been established. This trial assessed the pharmacokinetics (PK), safety, and efficacy of multiple…
Abstract Number: 0920 • ACR Convergence 2021
Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
Filip Van den Bosch¹, Denis Poddubnyy², Jayne Stigler³, Andrew Ostor⁴, Salvatore D'Angelo⁵, Victoria Navarro-Compán⁶, In-Ho Song³, Tianming Gao³, Fabiana Ganz³ and Lianne Gensler⁷, ¹Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL, ⁴Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁵Rheumatology Institute of Lucania (IReL) – Rheumatology Department of Lucania, “San Carlo” Hospital of Potenza and “Madonna delle Grazie” Hospital of Matera, Potenza, Italy, ⁶Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁷Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has demonstrated efficacy and safety through 14 weeks in the SELECT-AXIS 1 study in biologic disease-modifying antirheumatic…
Abstract Number: 1331 • ACR Convergence 2021
Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials
Arthur Kavanaugh¹, Yan Liu², Proton Rahman³, Philip Mease⁴, Laure Gossec⁵, Xie Xu², Elizabeth Hsia², May Shawi⁶, Chenglong Han², Marlies Neuhold⁷ and Atul Deodhar⁸, ¹University of California San Diego, La Jolla, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁵Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen-Cilag, Zug, Switzerland, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Anemia related to systemic inflammation can be an important feature of psoriatic arthritis (PsA). Hemoglobin (Hgb) levels have been shown to be inversely related…
Abstract Number: 1614 • ACR Convergence 2021
Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain
Sabrina Gmuca¹, Pamela Weiss¹, Mackenzie McGill¹, Maitry Sonagra², David D. Sherry¹, Peter Cronholm³, Jeffrey S. Gerber¹, Tonya M. Palermo⁴, Jami F. Young¹ and Abby R. Rosenberg⁴, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Cherry Hill, NJ, ³University of Pennsylvania, Philadelphia, PA, ⁴Seattle Children's Hospital, Seattle, WA
Background/Purpose: Chronic musculoskeletal pain (CMP) affects up to 40% of youth and is associated with physical disability and psychological distress. Resilience coaching interventions, such as…
Abstract Number: 1740 • ACR Convergence 2021
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Kenneth Kalunian³, Konstantina Psachoulia⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁴, ¹Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ²Monash University, Melbourne, Australia, ³University of California, La Jolla, CA, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…
Abstract Number: 1802 • ACR Convergence 2021
Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
Xenofon Baraliakos¹, Atul Deodhar², Roberto Ranza³, Simona Rednic⁴, Francesco Ciccia⁵, Fabiana Ganz⁶, Tianming Gao⁶, Apinya Lertratanakul⁶, In-Ho Song⁶, Andrew Ostor⁷ and Laura Coates⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Oregon Health & Science University, Portland, OR, ³Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ⁴Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, ⁵University of Campania “Luigi Vanvitelli", Naples, Italy, ⁶Abbvie Inc., North Chicago, IL, ⁷Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Axial, peripheral, and other disease manifestations often overlap between psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Upadacitinib (UPA) is an oral Janus kinase inhibitor…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0926 • ACR Convergence 2021
Predictors of 1-Year Treatment Response Among Upadacitinib-Treated Patients with Ankylosing Spondylitis: A Post Hoc Analysis
Marina Magrey¹, Sofia Ramiro², Marcelo Medeiros Pinheiro³, Tianming Gao⁴, Fabiana Ganz⁴, In-Ho Song⁴, Ana Biljan⁵, Nigil Haroon⁶ and Martin Rudwaleit⁷, ¹Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ²Leiden University Medical Center, Leiden, Netherlands, ³Universidade Federal de São Paulo, São Paulo, Brazil, ⁴AbbVie Inc., North Chicago, IL, ⁵Abbvie Inc., Chicago, IL, ⁶Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase inhibitor that has demonstrated efficacy and safety among patients with ankylosing spondylitis (AS) in the phase 2/3…
Abstract Number: 1332 • ACR Convergence 2021
Validation of the PROMIS-29 Profile in Patients with Active Psoriatic Arthritis Using Data from a Phase 3, Randomized, Placebo-Controlled Study Evaluating Guselkumab (TREMFYA®)
Ana-Maria Orbai¹, Laura Coates², Atul Deodhar³, Christopher Ritchlin⁴, Alexa Kollmeier⁵, Marlies Neuhold⁶, Yi-Hsuan Liu⁷, Yan Liu⁷ and Chenglong Han⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen-Cilag, Zug, Switzerland, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: It is important to assess symptoms of pain, fatigue, anxiety, depression, sleep disturbance, and impaired physical function in patients (pts) with psoriatic arthritis (PsA),…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 1741 • ACR Convergence 2021
Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials
Kenneth Kalunian¹, Maria Dall'Era², Richard Furie³, Eric Morand⁴, Konstantina Psachoulia⁵, Emmanuelle Maho⁶, Catharina Lindholm⁷ and Raj Tummala⁵, ¹University of California, La Jolla, CA, ²University of California San Francisco, San Francisco, CA, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In 2 phase 3 trials, TULIP-1 and TULIP-2, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 Here, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.